DIABETES Breaking news! Rosiglitazone and cardiovascular risk

被引：10
|
作者：
Kaul, Sanjay [1 ]
Diamond, George A. [1 ]
机构：
[1] Cedars Sinai Med Ctr, Div Cardiol, Los Angeles, CA 90048 USA
来源：
NATURE REVIEWS CARDIOLOGY | 2010年 / 7卷 / 12期
关键词：
MYOCARDIAL-INFARCTION; HEART-FAILURE; DEATH;
D O I：
10.1038/nrcardio.2010.160
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In the past 3 years, several studies have reignited the controversy regarding the cardiovascular risk associated with the use of rosiglitazone. Until a prospective, well-controlled, randomized clinical trial is performed to adjudicate the issue definitively, physicians should be free to exercise clinical judgment, and weigh the comparative risks and benefits of agents such as rosiglitazone on a case-by-case basis.
引用
收藏
页码：670 / 672
页数：4
相关论文
共 50 条
  • [21] Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
    Simo, Rafael
    Rodriguez, Angel
    Caveda, Elena
    CURRENT DRUG SAFETY, 2010, 5 (03) : 234 - 244
  • [22] THE POTENTIAL CARDIOVASCULAR RISK OF ROSIGLITAZONE COMPARING TO OTHER ANTI-DIABETES AGENTS: A RETROSPECTIVE DESCRIPTIVE STUDY
    Deng, Y.
    Guo, J. J.
    Lin, A. C.
    VALUE IN HEALTH, 2014, 17 (03) : A239 - A239
  • [23] Rosiglitazone may reduce insulin resistance related cardiovascular disease risk in patients with Type 2 diabetes
    Leonard, TB
    Bakst, A
    Warsi, G
    Bonora, E
    DIABETES, 2001, 50 : A441 - A441
  • [24] Treatment of type 2 diabetes with rosiglitazone associated with increased risk of cardiovascular events among older adults
    不详
    FORMULARY, 2008, 43 (02) : 79 - 80
  • [25] Rosiglitazone [Avandia] does not increase the risk of cardiovascular mortality and morbidity in patients with type 2 diabetes mellitus
    Reactions Weekly, 2008, 1206 (1) : 5 - 5
  • [26] Rosiglitazone treatment and cardiovascular disease in the Veterans Affairs Diabetes Trial
    Florez, H.
    Reaven, P. D.
    Bahn, G.
    Moritz, T.
    Warren, S.
    Marks, J.
    Reda, D.
    Duckworth, W.
    Abraira, C.
    Hayward, R.
    Emanuele, N.
    DIABETES OBESITY & METABOLISM, 2015, 17 (10): : 949 - 955
  • [27] Rosiglitazone treatment and cardiovascular disease in the veterans affairs diabetes trial
    Florez, H. J.
    Moritz, T.
    Marks, J.
    Reda, D.
    Warren, S.
    Duckworth, W.
    Abraira, C.
    DIABETOLOGIA, 2008, 51 : S370 - S370
  • [28] The Cardiovascular Safety of Diabetes Drugs - Insights from the Rosiglitazone Experience
    Hiatt, William R.
    Kaul, Sanjay
    Smith, Robert J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1285 - 1287
  • [29] Rosiglitazone may reduce insulin resistance-related cardiovascular disease risk in Type 2 diabetes patients
    Leonard, T
    Bakst, A
    Warsi, G
    Bonora, E
    DIABETOLOGIA, 2001, 44 : A222 - A222
  • [30] Beneficial effects of combined treatment with rosiglitazone and exercise on 40 cardiovascular risk factors in patients with type 2 diabetes
    Kadoglou, Nikolaos P. E.
    Iliadis, Fotios
    Liapis, Christos D.
    Perrea, Despina
    Angelopoulou, Nikoleta
    Alevizos, Miltiadis
    DIABETES CARE, 2007, 30 (09) : 2242 - 2244
12345